Sequella

Sequella licenses rights to SQ109 for TB to Maxwell Biotech

Tuesday, April 26, 2011

Sequella, a clinical-stage pharmaceutical company focused on commercializing antibiotics to treat life-threatening infectious diseases, and Maxwell Biotech Venture Fund have agreed to complete the clinical development and commercialization of SQ109 for treatment of tuberculosis (TB) in the Russian Federation and neighboring Commonwealth of Independent States (CIS), including Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine, according to Fierce Biotech.

[Read More]